Find out how to tackle one of the biggest challenges in treating cancer with Genomic testing for cancer treatment Read more
Genomic testing for breast cancer recurrence is guiding critical treatment decision making in early‑stage breast cancer patients, and helping clinicians avoid over and under treatment.
Eurobio Scientific’ EndoPredict® Breast Cancer Prognostic Test is a genomic test for breast cancer that accurately predicts the risk of breast cancer recurrence (return) up to 15 years and an individual’s benefit from chemotherapy,2,3 helping to guide key treatment decisions for every eligible woman with early-stage ER positive/HER2 negative breast cancer.
EndoPredict® is the most accurate prognostic test to guide early treatment decisions, providing an individual risk of breast cancer recurrence at 10 years.1,4
Some women will benefit more from chemotherapy than others – EndoPredict® provides the personalized chemobenefit for every patient to guide decision making.3
EndoPredict® is the only test to predict breast cancer recurrence risk up to 15 years, helping clinicians decide if extended endocrine therapy is needed.2
Watch the ESMO Satellite Symposium Recordings to continue the conversation around utilizing genomic testing for enhanced treatment decisions. Chaired by Prof. Pascal Pujol and Prof. Carsten Denkert, watching the recording from the symposium to dive into the world of prospective real-world data, confirming the predictive and prognostic power of EndoPredict®.
EndoPredict® gives important information to guide early treatment decisions for women with invasive primary breast cancer that is:
EndoPredict® is the only second generation gene expression test for breast cancer validated in premenopausal AND postmenopausal women who are lymph node positive or node negative2-8 – and the first with level of evidence 1A data,9,10 for confident treatment decisions.
EndoPredict® combines three factors – a molecular score, tumor size and nodal status – to give the EPclin Risk Score. The result is more prognostic information than first generation tests and assays that only measure gene expression, or clinical pathological factors alone.
The test has been developed and validated to include genes that predict both early and late recurrence (0-15 years). These improve prognostic value of EndoPredict® compared with classical prognostic factors and first generation tests.1,5,6
Learn more about EndoPredict®‘s superior accuracy here.
The EndoPredict® breast cancer prognosis test is a CE-marked in vitro diagnostic (IVD) test. It can be performed in local molecular pathology laboratories. The results are available within a few days and the test cost refund is assured for eligible patients in many countries.
EndoPredict® is available to order by clinicians via numerous local labs in your country.
EndoPredict® is available as a CE-marked IVD kit that can be run in local molecular pathology laboratories after a comprehensive onsite training, provided by Eurobio Scientific.